| International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer H Wildiers, P Heeren, M Puts, E Topinkova, MLG Janssen-Heijnen, ... Journal of clinical oncology 32 (24), 2595-2603, 2014 | 1687 | 2014 |
| Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients E Cotte, O Glehen, F Mohamed, F Lamy, C Falandry, F Golfier, FN Gilly World journal of surgery 31 (9), 1813-1820, 2007 | 198 | 2007 |
| Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as … M Ghielmini, K Rufibach, G Salles, L Leoncini-Franscini, ... Annals of Oncology 16 (10), 1675-1682, 2005 | 194 | 2005 |
| Biology of cancer and aging: a complex association with cellular senescence C Falandry, M Bonnefoy, G Freyer, E Gilson Journal of Clinical Oncology 32 (24), 2604-2610, 2014 | 168 | 2014 |
| Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs F Ranchon, G Salles, HM Späth, V Schwiertz, N Vantard, S Parat, ... BMC cancer 11, 1-10, 2011 | 161 | 2011 |
| 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The Lancet 393 (10191), 2591-2598, 2019 | 134 | 2019 |
| Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial C Falandry, B Weber, AM Savoye, F Tinquaut, O Tredan, E Sevin, ... Annals of oncology 24 (11), 2808-2813, 2013 | 120 | 2013 |
| Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum–paclitaxel-based chemotherapy, the GINECO experience J Alexandre, I Ray-Coquard, F Selle, A Floquet, P Cottu, B Weber, ... Annals of oncology 21 (12), 2377-2381, 2010 | 104 | 2010 |
| Inclusion of elderly patients in oncology clinical trials O Le Saux, C Falandry, HK Gan, B You, G Freyer, J Peron Annals of Oncology 27 (9), 1799-1804, 2016 | 103 | 2016 |
| Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer C Falandry, PA Canney, G Freyer, LY Dirix Annals of Oncology 20 (4), 615-620, 2009 | 99 | 2009 |
| CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation C Falandry, G Fourel, V Galy, T Ristriani, B Horard, E Bensimon, G Salles, ... Journal of Biological Chemistry 285 (26), 20234-20241, 2010 | 93 | 2010 |
| Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? AG Pallis, S Hatse, B Brouwers, G Pawelec, C Falandry, U Wedding, ... Journal of geriatric oncology 5 (2), 204-218, 2014 | 76 | 2014 |
| Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study C Falandry, M Debled, T Bachelot, T Delozier, J Cretin, P Romestaing, ... Breast cancer research and treatment 116, 501-508, 2009 | 67 | 2009 |
| Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting P Corbaux, D Maillet, A Boespflug, M Locatelli-Sanchez, M Perier-Muzet, ... European Journal of Cancer 121, 192-201, 2019 | 66 | 2019 |
| Association of immunotherapy with overall survival in elderly patients with melanoma M Perier-Muzet, E Gatt, J Péron, C Falandry, M Amini-Adlé, L Thomas, ... JAMA dermatology 154 (1), 82-87, 2018 | 63 | 2018 |
| Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross‐sectional survey (NutriAgeCancer) J Poisson, C Martinez‐Tapia, D Heitz, R Geiss, G Albrand, C Falandry, ... Journal of cachexia, sarcopenia and muscle 12 (6), 1477-1488, 2021 | 60 | 2021 |
| Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO/GCIG randomized … C Falandry, F Rousseau, MA Mouret-Reynier, F Tinquaut, D Lorusso, ... JAMA oncology 7 (6), 853-861, 2021 | 55 | 2021 |
| Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines C Falandry, M Campone, G Cartron, D Guerin, G Freyer European journal of cancer 46 (13), 2389-2398, 2010 | 53 | 2010 |
| Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors N Isambert, G Freyer, S Zanetta, B You, P Fumoleau, C Falandry, L Favier, ... Clinical Cancer Research 18 (6), 1743-1750, 2012 | 50 | 2012 |
| A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results N Isambert, G Freyer, S Zanetta, C Falandry, K Soussan Lazard, ... Journal of Clinical Oncology 26 (15_suppl), 3599-3599, 2008 | 50 | 2008 |
